Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01593696 · ClinicalTrials.gov registry record · Phase 1
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01593696: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01593696 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01593696, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
Background: \- Although progress has been made in treating children with B-cell cancers such as leukemia or lymphoma, many children do not respond to the standard treatments. One possible treatment involves collecting white blood cells called T cells from the person with cancer and modifying the cells to attack the B-cell cancer. The cells can then be given back to the participant. This study will use T cells that have been modified to attack the cluster of differentiation 19 (CD19) protein, which is found on the surface of some B-cell cancers. Objectives: \- To see if anti-CD19 modified white blood cells are a safe and effective treatment for children and young adults with advanced B-cell cancer. Eligibility: * Children and young adults between 1 and 30 years of age who have B-cell cancer (leukemia or lymphoma) that has not responded to standard treatments. * The leukemia or the lymphoma must have the CD19 protein. * There must be adequate organ function. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies or bone marrow biopsies may be performed depending on the type of cancer. * Participants will undergo a process where white blood cells are collected, called apheresis. These cells will be modified to contain the anti-CD19 gene. * Participants will have 3 days of chemotherapy to prepare their immune system to accept the modified cells. * Participants will receive an infusion of their own modified white blood cells. They will remain in the hospital until they have recovered from the treatment. * Participants will have frequent follow-up visits to monitor the outcome of the treatment. * If the participant benefits from the treatment, then he/she may have the option for another round of treatment.
Interventions
- BIOLOGICAL Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-06-29 |
| Est. Completion | 2017-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01593696
The ClinicalTrials.gov registry entry for NCT01593696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) is the first listed.
NCT01593696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01593696 about?
NCT01593696 is a clinical study titled "Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma". Background: \- Although progress has been made in treating children with B-cell cancers such as leukemia or lymphoma, many children do not respond to the standard treatments. One possible treatment involves collecting white blood cells called T cells from the person with cancer and modifying the ce...
What is the current status of trial NCT01593696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2012-06-29. Estimated completion is 2017-10-02.
What interventions are being tested in trial NCT01593696?
The interventions under investigation include: Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01593696?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.